[EQ] 2010 Global report on surveillance and response: Multidrug and extensively drug-resistant TB (M/XDR-TB)

de: Ruggiero, Mrs. Ana Lucia (WDC) : ruglucia@paho.org
fecha: 18 de marzo de 2010 14:28
asunto: [EQ] 2010 Global report on surveillance and response: Multidrug and extensively drug-resistant TB (M/XDR-TB)


Multidrug and extensively drug-resistant TB (M/XDR-TB)
2010 Global report on surveillance and response


World Health Organization, 2010…..Drug-resistant tuberculosis now at record levels….


Available online PDF [71p.] at: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf


18 MARCH 2010 | GENEVA | WASHINGTON DC – “……In some areas of the world, one in four people with tuberculosis (TB) becomes ill with a form of the disease that can no longer be treated with standard drugs regimens, a World Health Organization (WHO) report says.
For example, 28% of all people newly diagnosed with TB in one region of north western Russia had the multidrug-resistant form of the disease (MDR-TB) in 2008. This is the highest level ever reported to WHO. Previously, the highest recorded level was 22% in Baku City, Azerbaijan, in 2007.
In the new WHO's Multidrug and Extensively Drug-Resistant Tuberculosis: 2010 Global Report on Surveillance and Response, it is estimated that 440 000 people had MDR-TB worldwide in 2008 and that a third of them died. In sheer numbers, Asia bears the brunt of the epidemic. Almost 50% of MDR-TB cases worldwide are estimated to occur in China and India. In Africa, estimates show 69 000 cases emerged, the vast majority of which went undiagnosed…..”


Content:
Summary Introduction Part I: Surveillance of M/XDR-TB 1.1 Geographical coverage of anti-TB drug resistance data
1.2 Resistance to first-line anti-TB drugs, including MDR-TB
1.3 Risk factors for drug resistance: previous treatment, sex and HIV
1.4 Trends over time
1.5 Resistance to second-line anti-TB drugs, including XDR-TB
1.6 Estimated global burden of MDR-TB
Part II: Progress in the global response to M/XDR-TB 2.1 Scaling up laboratory services for diagnosis of M/XDR-TB
2.2 Reporting of MDR-TB patients and their treatment outcomes
2.3 Addressing other health systems considerations for the response to M/XDR-TB
2.4 Financing the care of drug-resistant TB patients in the 27 high MDR-TB burden countries
References
Annexes


* * *